Seven days treatment with the angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients; a placebo-controlled randomised multi-centre double-blind phase 2 trial
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2021.01.26.21250511: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: Informed consent was obtained from each patient prior to any trial-related procedure. Randomization The patients were randomly assigned in a 1:1 ratio to receive either C21 or placebo in blocks of four, with randomization stratified by trial site. Blinding Patients, care providers and those assessing outcomes were kept blinded until data base lock had been performed for the complete trial. Power Analysis Statistical analyses: The original sample size calculation on the primary endpoint indicated that 75 patients per group were needed to achieve 80% power to detect a difference in reduction of CRP in C21 treated patients compared to placebo using a two-sided … SciScore for 10.1101/2021.01.26.21250511: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: Informed consent was obtained from each patient prior to any trial-related procedure. Randomization The patients were randomly assigned in a 1:1 ratio to receive either C21 or placebo in blocks of four, with randomization stratified by trial site. Blinding Patients, care providers and those assessing outcomes were kept blinded until data base lock had been performed for the complete trial. Power Analysis Statistical analyses: The original sample size calculation on the primary endpoint indicated that 75 patients per group were needed to achieve 80% power to detect a difference in reduction of CRP in C21 treated patients compared to placebo using a two-sided t-test at 10% significance level. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04452435 Completed Safety and Efficacy of C21 in Subjects With COVID-19 Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from scite Reference Check: We found no unreliable references.
About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.
-
